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Abstract
Background The RECOURSE trial showed clinical efficacy for trifluridine/tipiracil for refractory metastatic colorectal cancer 
patients. We assessed the feasibility and effectiveness of trifluridine/tipiracil in daily clinical practice in The Netherlands.
Methods Medical records of patients from 17 centers treated in the trifluridine/tipiracil compassionate use program were 
reviewed and checked for RECOURSE eligibility criteria. Baseline characteristics, safety, and survival times were compared, 
and prespecified baseline characteristics were tested in multivariate analyses for prognostic significance on overall survival 
(OS).
Results A total of 136 patients with a median age of 62 years were analyzed. Forty-three patients (32%) did not meet the 
RECOURSE eligibility criteria for not having received all prior standard treatments (n = 35, 26%) and/or ECOG performance 
status (PS) 2 (n = 12, 9%). The most common grade ≥3 toxicities were neutropenia (n = 44, 32%), leukopenia (n = 8, 6%), 
anemia (n = 7, 5%), and fatigue (n = 7, 5%). Median progression-free survival (PFS) and median OS were 2.1 (95% CI, 
1.8–2.3) and 5.4 months (95% CI, 4.0–6.9), respectively. Patients with ECOG PS 2 had a worse median OS (3.2 months) 
compared to patients with ECOG PS 0–1 (5.9 months). ECOG PS, KRAS-mutation status, white blood cell count, serum 
lactate dehydrogenase, and alkaline phosphatase were prognostic factors for OS.
Conclusions Our data show that treatment with trifluridine/tipiracil in daily clinical practice is feasible and safe. Differences 
in patient characteristics between our population and the RECOURSE study population should be taken into account in the 
interpretation of survival data. Our results argue against the use of trifluridine/tipiracil in patients with ECOG PS 2.
Funding Johannes J.M. Kwakman received an unrestricted research grant from Servier.
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Introduction
Recently, trifluridine/tipiracil (TAS-102) has shown effi-
cacy in refractory metastatic colorectal cancer (mCRC). The 
randomized phase 3 RECOURSE trial showed a significant 
increase in median overall survival (OS) of 1.8 months com-
pared to placebo in refractory mCRC patients [1]. Trifluri-
dine is a thymidine analogue that is incorporated into DNA, 
causing its antitumor effect [2]. Tipiracil hydrochloride pre-
vents the rapid degradation of trifluridine, which allows for 
continuous adequate plasma levels of trifluridine [3, 4].
Clinical trial results provide the backbone of evidence-
based medicine and are incorporated in clinical guidelines. 
However, a trial population may not always be a representa-
tive sample of the total population because of restrictive trial 
eligibility criteria. For example, in the RECOURSE study 
only patients with an Eastern Cooperative Oncology Group 
performance status (ECOG PS) of 0 or 1 were included. 
Also, the controlled conditions under which clinical trials 
are usually performed cannot always be guaranteed in gen-
eral practice. Hence, the use of observational data of non-
trial patients may be helpful to assess the feasibility and 
effectiveness of novel treatments in daily clinical practice.
After publication of the results of RECOURSE [1], a 
compassionate use program for trifluridine/tipiracil in refrac-
tory mCRC patients was initiated in The Netherlands before 
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market access January 2017. We analyzed the baseline char-
acteristics of these patients with the RECOURSE eligibil-
ity criteria and assessed the feasibility and effectiveness of 
trifluridine/tipiracil treatment in this non-trial population. 
Finally, these data allowed us to evaluate patient and tumor 
characteristics for prognostic significance on OS.
Methods
Patients
Physicians who registered patients between December 2015 
and January 2017 for the trifluridine/tipiracil compassionate 
use program in The Netherlands were invited to participate 
in the study. Participation criteria for the compassionate use 
program were comparable but not equal to the eligibility 
criteria of the RECOURSE study and included a biopsy-
confirmed adenocarcinoma of the colon or rectum with 
the presence of metastatic lesions. Patients were required 
to have received at least two prior regimens of standard 
chemotherapies, which may have included adjuvant chemo-
therapy if a tumor had recurred within 6 months, and expo-
sure to a fluoropyrimidine, oxaliplatin, irinotecan, bevaci-
zumab, and, for patients with (K)RAS-wild-type tumors, an 
anti-epidermal growth factor receptor (EGFR) monoclonal 
antibody. Patients must have been refractory to those thera-
pies or significant adverse events must have precluded their 
readministration. In addition, patients must have adequate 
bone marrow, liver, and renal function. Medical records of 
patients were reviewed, and baseline clinicopathological fac-
tors including (but not limited to) sex, age, disease charac-
teristics, prior systemic regimens, (K)RAS-mutation status, 
ECOG PS, serum lactate dehydrogenase (LDH), alkaline 
phosphatase (ALP), white blood cell count (WBC), num-
ber of trifluridine/tipiracil cycles, toxicities, number of dose 
delays and dose reductions, disease response, date of pro-
gression, and date of death were collected. All patients pro-
vided written informed consent for the treatment. The study 
was reviewed by the Medical Ethics Review Committee of 
the Academic Medical Center, Amsterdam, who decided 
that the Medical Research Involving Human Subjects Act 
(WMO) did not apply to the study.
Treatment
According to the RECOURSE study, the recommended dose 
of trifluridine/tipiracil treatment was 35 mg/m2 twice daily, 
for 5 days per week with 2 days of rest for 2 weeks, fol-
lowed by 2 weeks of rest. This schedule was repeated every 
4 weeks until disease progression, unacceptable toxicity, or 
patient refusal occurred.
Outcomes
Patient baseline characteristics were checked for 
RECOURSE eligibility and compared to the RECOURSE 
study population. Study endpoints included safety, median 
OS, median progression-free survival (PFS), and disease 
control rate (DCR). The survival times and DCR of eli-
gible and ineligible patients were compared. Last, pre-
specified variables were evaluated for prognostic sig-
nificance on OS. All toxicities were scored according to 
National Cancer Institute Common Terminology Criteria 
for Adverse Events (NCI CTCAE), version 4.0. Tumor 
response was evaluated according to RECIST 1.1 at inter-
vals at the discretion of the treating physicians.
Statistical analysis
Patients who received at least one dose of trifluridine/tip-
iracil were included in the analysis. Descriptive statistics 
and frequency tables were used to characterize the study 
population. PFS was defined as the time from trifluridine/
tipiracil initiation to the date of first documented progres-
sion or death from any cause. OS was defined as the time 
from treatment initiation to the date of death from any cause. 
Median PFS and OS were estimated with the Kaplan–Meier 
method and compared with Cox proportional hazard models. 
Patients alive or alive without progression at last follow-up 
were censored for OS and PFS, respectively. The response 
rate (RR) represents the proportion of patients with com-
plete or partial response. DCR represents the proportion of 
patients with complete response, partial response, or stable 
disease, and was compared with Fisher’s exact test.
Prespecified variables for the identification of poten-
tial prognostic factors on OS were categorized based on 
clinical reasoning and taking subgroup sizes into account 
as follows: sex (male versus female), age (<70 years ver-
sus ≥70 years), resection of primary tumor (yes versus 
no), tumor sidedness (right colon versus left colon and 
rectum with splenic flexure as differentiation), number of 
metastatic sites (1 versus 2 and ≥3), presence of perito-
neal metastases (yes versus no), exposure to all standard 
treatments (yes versus no), time from diagnosis of metas-
tases and start treatment (<18 months versus ≥18 months), 
ECOG PS (0 versus 1 or 2), LDH (<350 versus ≥350 U/l), 
WBC (<8.0 versus  ≥8.0  ×  109/l), ALP (<200 ver-
sus ≥200 U/l), and (K)RAS-mutation status (mutated ver-
sus wild type). Multivariate associations between these 
variables and OS were examined using a Cox regression 
model from which hazard ratios (HR) were obtained with 
95% confidence intervals (CI). p values less than 0.05 were 
considered to indicate statistical significance.
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Results
Study population
A total of 148 registered patients from 17 centers were 
reviewed. Trifluridine/tipiracil treatment was started in 
136 patients, who were further analyzed. Twelve patients 
(9%) did not fulfill the RECOURSE study eligibility cri-
teria because of an ECOG PS of 2 at the time of treat-
ment initiation. Eight patients (6%) had not received at 
least two prior regimens. Of these patients, 4 were con-
sidered unfit for treatment with second-line oxaliplatin or 
irinotecan, 3 had had significant toxicity upon adjuvant 
chemotherapy (>6 months before to metastatic disease) 
that precluded the readministration of a fluoropyrimidine 
(n = 2) or oxaliplatin (n = 1), and 1 was treated with a 
combination of a fluoropyrimidine, oxaliplatin, irinotecan, 
and bevacizumab as the only prior regimen. An additional 
35 patients (42 in total, 31%) did not receive all standard 
treatments, of which 5 patients were not retreated with 
oxaliplatin because of significant toxicities in the adju-
vant setting, 3 patients refused irinotecan treatment, and 
3 and 1 patients were considered unfit for oxaliplatin and 
irinotecan, respectively. A total of 37 patients (27%) were 
not pretreated with bevacizumab, 30 for unknown reasons 
and 7 for medical considerations. All patients with a (K)
RAS-wild-type tumor had received anti-EGFR monoclonal 
antibodies. A total of 43 patients (32%) were considered 
to be ineligible according to the RECOURSE eligibility 
criteria. Compared to the RECOURSE study popula-
tion, more patients were male (68% versus 61%), more 
patients had ECOG PS 1 (57% versus 44%) or 2 (9% versus 
0%), fewer patients had received all standard treatments 
(69% versus 100%), or had been refractory to fluoropy-
rimidines (90% versus 98%), or had a (K)RAS-wild-type 
tumor (39% versus 49%). The main baseline characteristics 
of RECOURSE study patients and our non-trial popula-
tion, with differentiation between ineligible and eligible 
patients, are listed in Table 1.
Safety
All patients started treatment at the recommended dose. 
The median number of cycles was 2 (range, 1–10). At the 
time of the analysis, 123 patients (90%) had discontinued 
treatment of which 5 (4%) resulted from treatment-related 
toxicities. Five patients (4%) were hospitalized because of 
treatment-related adverse events, which included febrile 
neutropenia in 3 patients, and 1 patient each for ileitis and 
a combination of mucositis, nausea, and vomiting, respec-
tively. There were no treatment-related deaths. A total of 
38 dose reductions were applied in 31 patients (23%), with 
26 (19%), 3 (2%), and 2 (1%) patients having 1, 2, or 3 
reductions, respectively. Dose delays were applied in 53 
patients (39%; range, 0–7). The most common grade ≥3 
adverse event was neutropenia (n = 44, 32%). Grade ≥3 
leukopenia, anemia, and fatigue were reported in 8 (6%), 
7 (5%), and 7 (5%) patients, respectively. Other commonly 
observed toxicities included nausea, anorexia, and diar-
rhea, but these events were mostly limited to grade 1 and 
2 (Table 2).
Compared to the RECOURSE population, fewer grade ≥3 
events (69% versus 44%) and serious events (30% versus 4%) 
were reported, whereas dose reductions were applied in a 
greater proportion of patients (14% versus 23%). A compa-
rable number of patients discontinued treatment because of 
adverse events (4% versus 4%).
Efficacy
After a median follow-up of 4.2 months, 120 patients (88%) 
had progressed and 93 patients had died (68%). Median PFS 
was 2.1 months (95% CI, 1.8–2.3; Fig. 1), and median OS 
was 5.4 months (95% CI, 4.0–6.9; Fig. 2). A total of 132 
patients were evaluated for response. Two patients had a 
partial response and 35 patients had stable disease, resulting 
in a RR of 2% and DCR of 28%.
These outcomes are worse when compared to the out-
comes of the RECOURSE study population (Table  3). 
Patients who were ineligible according to the RECOURSE 
study criteria had superior efficacy results compared 
to eligible patients, with a DCR of 48% versus 20% 
(p = 0.002), median PFS of 2.8 months (95% CI, 1.2–4.4) 
versus 2.0 months (1.9–2.2; HR, 0.53, 95% CI, 0.35–0.81; 
p = 0.003) and median OS of 8.2 months (5.0–11.4) ver-
sus 4.8 months (3.6–6.0; HR, 0.61, 95% CI, 0.38–0.95; 
p = 0.04). Subgroup analyses indicated that the subgroup 
of patients who did not receive all standard therapies 
before trifluridine/tipiracil (for reasons not meeting the 
RECOURSE eligibility criteria, n = 35) had a superior 
median OS (8.5 months; 95% CI, 5.2–11.8) as compared 
to patients who were fully pretreated [or significant adverse 
events precluded the readministration of any of those ther-
apies; n = 101; median OS, 4.7 months (3.6–5.8); HR, 
0.51, 95% CI, 0.30–0.85; p = 0.01]. Patients with ECOG 
PS 0–1 (n = 124) had a median OS of 5.9 months (95% 
CI, 4.4–7.3), compared to 3.2 months (1.4–5.0) for patients 
with ECOG PS 2 (n = 12; HR, 0.79, 95% CI, 0.36–1.71; 
p = 0.54). Median OS was 4.6 months (95% CI, 4.0–5.1) 
and 6.9 months (4.2–9.7) for patients with a KRAS-mutated 
tumor (n = 83) and KRAS-wild-type tumor (n = 53), respec-
tively (HR, 1.67, 95% CI, 1.08–2.59; p = 0.02).
Six of the prespecified variables were identified as prog-
nostic for OS in univariate Cox regression analysis: ECOG 
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PS, KRAS-mutation status, exposure to all standard treat-
ments, WBC, serum LDH, and ALP (Table  4). ECOG 
PS, KRAS-mutation status, WBC, serum LDH, and ALP 
remained statistically significant in multivariate analysis.
Discussion
We assessed the feasibility and effectiveness of trifluridine/
tipiracil in refractory mCRC patients who were treated in a 
national compassionate use program. Our data indicate that 
treatment with trifluridine/tipiracil is feasible and safe in 
daily clinical practice.
Trifluridine/tipiracil was generally well tolerated, with 
neutropenia as the most frequently observed grade ≥3 
adverse event. Three patients were hospitalized for febrile 
neutropenia. The incidence of nonhematological grade ≥3 
toxicities was low, which reflects the low number of patients 
who discontinued treatment for adverse events. No major 
new safety concerns were observed in this non-trial popu-
lation. Although the incidence of any grade toxicities was 
somewhat lower in our predominantly Caucasian popula-
tion compared to the global RECOURSE study population, 
the overall safety profile was comparable, suggesting that 
there are no ethnic differences in the tolerability of trifluri-
dine/tipiracil. Similar findings have been reported in a sub-
group analysis of Spanish RECOURSE study patients [5], 
in contrast to the safety profile of fluoropyrimidines, where 
regional disparities have led to different dosing schedules 
[6, 7].
The effectiveness of trifluridine/tipiracil in our patients 
treated outside the context of a trial appeared to be inferior 
to the outcomes in the RECOURSE study. Several comments 
can be made on this issue.
There are multiple differences between the base-
line characteristics of our population and that of the 
Table 1  Baseline characteristics
ECOG Eastern Cooperative Oncology Group
a In metastatic setting or as adjuvant treatment <6 months before recurrent disease
Recourse Compassionate use program
Trifluridine/
tipiracil group
All patients Eligible patients Ineligible patients
n = 534 (%) n = 136 (%) n = 93 (%) n = 43 (%)
Sex
 Male 326 (61) 92 (68) 63 (68) 29 (67)
 Female 208 (39) 44 (32) 30 (32) 14 (33)
Age (years, median), range 63 (27–82) 62 (30–88) 61 (30–81) 65 (34–88)
ECOG performance status
 0 301 (56) 46 (34) 33 (36) 12 (28)
 1 233 (44) 78 (57) 60 (65) 19 (44)
 2 0 (0) 12 (9) 0 (0) 12 (28)
KRAS-mutation
 No 262 (49) 53 (39) 33 (36) 20 (47)
 Yes 272 (51) 83 (61) 60 (65) 23 (54)
Time from diagnosis of metastases
 <18 months 111 (21) 29 (21) 18 (19) 11 (26)
 ≥18 months 423 (79) 107 (79) 75 (81) 32 (74)
Number of prior regimens
 1 0 (0) 8 (6) 3 (3) 5 (12)
 2 95 (18) 54 (40) 36 (39) 18 (42)
 3 119 (22) 56 (41) 41 (44) 15 (35)
 ≥4 320 (60) 18 (13) 13 (14) 5 (12)
Prior systemic anticancer agents a a a
 Fluoropyrimidine 534 (100) 134 (99) 91 (98) 43 (100)
 Oxaliplatin 534 (100) 121 (89) 90 (97) 31 (72)
 Irinotecan 534 (100) 128 (94) 93 (100) 35 (81)
 Bevacizumab 534 (100) 99 (73) 86 (93) 12 (28)
 Anti-EGFR monoclonal antibodies 278 (52) 53 (39) 33 (36) 20 (47)
Refractory to fluoropyrimidine 524 (98) 123 (90) 84 (90) 39 (91)
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RECOURSE study population. Our population had a 
worse overall health status, with 57% and 9% having an 
ECOG PS of 1 or 2, respectively, compared to 44% and 
0% in the RECOURSE study population, respectively. 
Although the scoring of performance status by physicians 
may not be optimal [8], it is an established prognostic 
factor in mCRC and in refractory mCRC in particular [9, 
10] and was identified as a prognostic parameter in the 
RECOURSE study. This aspect is reflected in the poor out-
comes that we observed in patients with ECOG PS 2. Our 
data confirm the worse outcomes of trifluridine/tipiracil in 
patients with KRAS-mutated tumors compared to KRAS-
wild-type tumors, and our patients had a higher incidence 
of KRAS-mutated tumors compared to the RECOURSE 
patients (61% versus 51%, respectively).
On the other hand, fewer patients in our population were 
exposed to all available standard therapies before trifluri-
dine/tipiracil treatment, which in this subgroup was asso-
ciated with a better outcome, suggesting that trifluridine/
tipiracil may have better efficacy in earlier lines of treat-
ment, as is currently being investigated. Three phase 2 stud-
ies in mCRC patients are ongoing, investigating trifluridine/
tipiracil in combination with bevacizumab as maintenance 
therapy following fluoropyrimidine-based induction therapy 
(ALEXANDRIA), studying trifluridine/tipiracil in combi-
nation with nivolumab in patients with refractory micro-
satellite stable mCRC, and comparing trifluridine/tipiracil 
with capecitabine, both with the addition of bevacizumab, 
as first-line treatment in patients who are not eligible for 
combination chemotherapy (TASCO1), respectively (Clini-
calTrials.gov identifiers: NCT02654639, NCT02860546, 
and NCT02743221).
Table 2  Treatment-related adverse events (AEs)
AE adverse event
n = 136 (%)
Any AEs 103 (76)
Grade ≥3 AEs 60 (44)
Nonhematological grade ≥3 AEs 16 (12)
Most common AEs, any grade
 Diarrhea 16 (12)
 Nausea 26 (19)
 Vomiting 7 (5)
 Anorexia 21 (15)
 Mucositis 9 (7)
 Fatigue 50 (37)
Grade ≥3 laboratory abnormalities
 Neutropenia 44 (32)
 Leukopenia 8 (6)
 Anemia 7 (5)
 Thrombocytopenia 1 (1)
 Increased total bilirubin 2 (2)
Serious AEs 5 (4)
 Resulting from febrile neutropenia 3 (2)
 Resulting from gastrointestinal toxicities 2 (2)
Fig. 1  Kaplan–Meier curve of progression-free survival
Fig. 2  Kaplan–Meier curve of overall survival
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Other factors that may influence a comparison between 
our efficacy results and those of the RECOURSE study 
are discrepancies in survival time calculations (time from 
the start of treatment versus time from randomization, 
respectively, until date of event), analyzed population (only 
patients who received at least one dose of trifluridine/tip-
iracil were included in our analyses), and disease evaluation. 
Patients in the RECOURSE study were required to have a 
disease evaluation at least every two cycles, whereas a sub-
stantial number of patients in the compassionate use pro-
gram had their first disease evaluation after three cycles (i.e., 
12 weeks). This difference may have distorted the median 
PFS in our population positively while affecting the DCR 
negatively.
The superior efficacy of trifluridine/tipiracil com-
pared to placebo in the RECOURSE study was observed 
in all prespecified subgroups [1]. However, the diverging 
Kaplan–Meier curves for PFS at the time of the first dis-
ease evaluation suggest that only a subgroup of patients may 
benefit from trifluridine/tipiracil treatment. Kasi et al. and 
Hamauchi et al. demonstrated that the occurrence of neutro-
penia was associated with better prognosis and postulated 
that dose escalation of trifluridine/tipiracil in patients with-
out neutropenia should be further investigated to improve 
treatment outcomes in these patients [11, 12]. Moreover, 
potential predictive genetic biomarkers for trifluridine/tip-
iracil therapy have been identified [13].
In patients with limited life expectancy, the use of poten-
tially harmful end-of-life treatments should be questioned 
[14]. A proper clinical selection may be helpful to reduce 
the number of patients who will be unnecessarily exposed 
to toxicity and to increase cost-effectiveness. Although 
numerous prognostic parameters have been identified in 
newly diagnosed mCRC patients [15], limited data are 
available in heavily pretreated mCRC patients. ECOG PS, 
elapsed time since diagnosis of first metastasis, and number 
of metastatic sites were identified as prognostic variables in 
the RECOURSE study [1]. Pietrantonio et al. developed a 
predictive nomogram for the 12-week death probability in 
refractory mCRC patients, with the use of four easy-to-col-
lect variables including ECOG PS, serum LDH, resection of 
primary tumor, and presence of peritoneal metastases, that 
may improve the selection of patients for later-line therapies 
[10]. Our relatively small cohort suggested that poor ECOG 
PS, a KRAS-mutated tumor, and elevated levels of serum 
LDH, WBC, and ALP are associated with poorer survival 
outcomes upon trifluridine/tipiracil treatment. These vari-
ables may help clinicians to estimate the prognosis in these 
patients, but further research to validate these findings is 
needed. Tumor sidedness was not prognostic, which con-
firms the lack of prognostic value of this parameter in a 
refractory setting [16].
In conclusion, our data show that treatment with trifluri-
dine/tipiracil in daily clinical practice is feasible. The drug 
was generally well tolerated, with a safety profile compa-
rable to that of the global RECOURSE study population. 
Our data argue against the use of trifluridine/tipiracil in 
refractory mCRC patients with poor performance status, 
although the outcomes in less heavily pretreated patients 
support future studies in earlier lines of treatment. Further 
research to identify predictive factors to reduce the number 
of patients who would be unnecessarily exposed to toxicity 
and to increase cost-effectiveness is warranted.
Table 3  Treatment outcomes
CI confidence interval
a Denominator is the number of patients evaluated for response
Recourse Compassionate use program
Trifluridine/tip-
iracil group
All patients Eligible patients Ineligible patients
n = 534 (%) n = 136 (%) n = 93 (%) n = 43 (%)
Overall  responsea 6 (1.6) 2 (2) 0 (0) 2 (5)
Disease  controla 221 (44) 37 (28) 18 (20) 19 (48)
Progression-free 
survival (months, 
median), 95% CI
2.0 (1.9–2.1) 2.1 (1.8–2.3) 2.0 (1.9–2.2) 2.8 (1.2–4.4)
Overall survival 
(months, median), 
95% CI
7.1 (6.5–7.8) 5.4 (4.0–6.9) 4.8 (3.6–6.0) 8.2 (5.0–11.4)
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